Skip to main content
Equibles
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd

Track TEVA — free

Use TEVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TEVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$44.50 +0.85 (+1.95%) At close · Nov 13
Rebalance outlook locked
Market Cap
$51.92B
Shares
1.17B
Volume · Nov 13 7.56M Avg daily vol (3M) 6.03M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.50 Open$43.91 Day$43.43–44.57 52W close$24.21–44.50 Avg vol 30d7.2M Short int27.7M · 2.4% of shares · 5.3d Short vol26% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Next earnings call
Jan 27, 2027 Est · unconfirmed · in 10 wks
Q3 2026 earnings call transcript
call held Nov 3, 2026
Play latest call

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue Falls 2% as Gross Margin Expands

Teva reported revenue of $4,395 million in the third quarter of 2026, down 2%, while gross profit margin rose to 55.5% from 51.4%. It completed the BioXcel acquisition for $58 million upfront and up to $68 million in contingent payments.

Revenue $4.4B ▼ 1.9% Net income $233M ▼ 46.2% Diluted EPS $0.20 ▼ 45.9%
Read from the MD&A section
3 source passages
Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Under the terms of the agreement, Teva will acquire the assets for an upfront payment of $58 million and up to an additional $68 million in contingent payments. Open the document at this passage
Nov 3
Earnings call
Innovative growth supports raised 2026 guidance

Teva raised 2026 full-year revenue guidance to $16.7 billion to $17 billion and free cash flow guidance to $2.1 billion to $2.4 billion, citing strong innovative-product performance.

Read from the first part of this long document
5 source passages
Turning to 2026 outlook on slide 33. Based on our strong performance year-to-date and the visibility into the reminder of the year, we are raising our full-year revenue guidance range to $16.7 billion to $17 billion, which is an increase of $175 million to our midpoint. We are also increasing our guidance for free cash flow to be in the range of $2.1 billion to $2.4 billion for the full year. Our innovative portfolio continues to perform strongly across all three products, OSTEDO, AJOVI, and UZEDE. this is a milestone for Teva, but more importantly, a milestone and an advancement of treatment for patients living with schizophrenia. Open the document at this passage
Nov 3
Current report 8-K
Innovative brands grow 33% as 2026 outlook rises

Teva Pharmaceutical Industries Ltd. reported third-quarter revenues of $4.4 billion, down 2% year-over-year, while AUSTEDO, AJOVY and UZEDY drove 33% growth; gross margin expanded to 55.5%, and the company raised 2026 revenue guidance to $16.7–$17.0 billion.

Financial results Read from the first part of this long document
5 source passages
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026. Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025 Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Revenues: $16.7–$17.0 billion Open the document at this passage
Oct 29
Current report 8-K Events of Oct 27
Director or officer change, or executive pay

Teva Pharmaceutical Industries Ltd. elected Dr. David J. Brailer as an independent Board member effective November 3, 2026, serving until Teva’s 2027 annual meeting of shareholders.

Oct 9
Investor event
WELTRUZA™ (olanzapine) Approval – Conference Call

Teva’s Welltruza won US FDA approval as a once-monthly subcutaneous olanzapine long-acting injectable with no loading dose or oral supplementation. Teva expects meaningful revenue in the second half of next year and set the WAC price at $3,950.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$14.02B
Trailing 12 months
Net income (TTM)
$507.00M
Trailing 12 months
Revenue growth YoY
-1.9%
Year over year
Operating margin
10.2%
Trailing 12 months
P / E (TTM)
101.1
Trailing earnings · reciprocal yield 1.0%
FCF yield
2.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.6%
Year over year · more shares
Price change (1Y)
+74.2%
Trailing year
Short interest
2.4%
Latest settlement · 5.3 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼5.1% $4.23B −$217.00M '24 Q4* ▲1.9% $3.89B $214.00M '25 Q1 ▲0.3% $4.18B $282.00M '25 Q2 ▲3.4% $4.48B $433.00M '25 Q3 ▼64.5% $1.50B $481.00M '25 Q4* ▲2.3% $3.98B $369.00M '26 Q1 ▼0.8% $4.14B −$576.00M '26 Q2 LATEST ▼1.9% $4.39B $233.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg +11%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 100%
near high
Momentum
relative strength
Very Strong
1-month return +7%
trailing
6-month return +29%
trailing
YTD return +43%
this year
Relative strength +28%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $40 › 200d $35 — 50d above 200d
Institutional flow Accumulating
625 of 685 funds reported for Sep 30 · net +18.4M sh shares · +72 new
Insider flow Distributing
Net -$22.7M over 90 days · 100% sells
Short interest Falling
2.38% of shares out · ▼ -1.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
685 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Strong
Revenue growth +4%
Y/Y
Gross margin 52%
expanding
EPS growth +183%
Y/Y
Free cash flow $1.1B
Valuation P/E 101.1
rich
Buyback $2.1B
authorized
Quant / Vol
risk profile
Moderate
Volatility 34%
annualized · 1-yr
Max drawdown −22%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the Earnings Call filed Jul 29, 2026
Non-GAAP gross margin · full year 2026 Non-GAAP Maintained 54.5% – 55.5%
Apr 29, 2026 54.5% – 55.5% changed to Jul 29, 2026 54.5% – 55.5%
Previous outlook earlier release · from the 8-K filed Apr 29, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow · 2026 $2B – $2.4B
Net savings · by 2027 $700M
Non-GAAP operating income margin · by 2027 30%
Guided vs delivered · last 4 settled
Full-year revenue full year 2025
guided $16.8B – $17B
$17.26B Beat +2.1%
Revenues Full year 2024
guided $15.7B – $16.3B
$16.54B Beat +3.4%
Revenues Full year 2023
guided $14.8B – $15.4B
$15.85B Beat +4.9%
Revenues 2022
guided $15.4B – $16B
$14.93B Miss −4.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
+11% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
100% Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $40 › 200d $35 — 50d above 200d
Institutional flow Accumulating
625 of 685 funds reported for Sep 30 · net +18.4M sh shares · +72 new
Insider flow Distributing
Net -$22.7M over 90 days · 100% sells
Short interest Falling
2.38% of shares out · ▼ -1.2% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
685 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $45 · 100% Range high $45
vs 200-day avg +27% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Argentinian peso decrease in value against the U.S. dollar 19% the second quarter of 2026 filing —
Australian dollar increase in value against the U.S. dollar 11% the second quarter of 2026 filing —
Brazilian real increase in value against the U.S. dollar 12% the second quarter of 2026 filing —
contingent consideration 17M the three months ended June 30, 2026 filing —
Employee termination 37M Three months ended June 30, 2026 filing —
euro increase in value against the U.S. dollar 3% the second quarter of 2026 filing —
Europe profit 367M Three months ended June 30, 2026 filing —
exit market share 32.5% second quarter of 2026 filing —
free cash flow non-GAAP 622M second quarter of 2026 filing —
Hungarian forint increase in value against the U.S. dollar 15% the second quarter of 2026 filing —
impairments of tangible assets 91M the three months ended June 30, 2026 filing —
Indian rupee decrease in value against the U.S. dollar 9% the second quarter of 2026 filing —
International Markets profit 99M Three months ended June 30, 2026 filing —
Mexican peso increase in value against the U.S. dollar 12% the second quarter of 2026 filing —
milestone payment 5M the first quarter of 2026 filing —
new Israeli shekel increase in value against the U.S. dollar 21% the second quarter of 2026 filing —
Non-GAAP net income attributable to Teva non-GAAP $21M three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP Net income (Loss) attributable to Teva -576M
+139M Amortization of purchased intangible assets
+230M Legal settlements and loss contingencies
+113M Impairment of long-lived assets
+38M Restructuring costs
+40M Equity compensation
+17M Contingent consideration
+8M Financial expenses
+29M Other non-GAAP items
-17M Corresponding tax effects and unusual tax items
= Non-GAAP net income attributable to Teva 21M
Non-GAAP tax rate non-GAAP 86.7% three months ended June 30, 2026 filing —
Polish złoty increase in value against the U.S. dollar 3% the second quarter of 2026 filing —
Profit (loss) of Other Activities -16M Three months ended June 30, 2026 filing —
restructuring expenses 38M the three months ended June 30, 2026 filing —
revenues denominated in currencies other than the U.S. dollar 45% the second quarter of 2026 filing —
Russian ruble increase in value against the U.S. dollar 8% the second quarter of 2026 filing —
share of total U.S. generic prescriptions 6.1% second quarter of 2026 filing —
Swiss franc increase in value against the U.S. dollar 5% the second quarter of 2026 filing —
total prescriptions 237M second quarter of 2026 filing —
Total reportable segments profit 391M Three months ended June 30, 2026 filing —
Ukrainian hryvna decrease in value against the U.S. dollar 6% the second quarter of 2026 filing —
United States profit (loss) -76M Three months ended June 30, 2026 filing —
upfront payment 15M the second quarter of 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TEVA
Teva Pharmaceutical Industries Ltd
this stock
$51.92B +42.6% +4.3% 101.1 2.4%
TAK
Takeda Pharmaceutical Co Ltd
 $68.47B +37.5% — — 0.1%
GALDY
Galderma Group AG
 $53.23B +10.1% — — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.0%
HLN
Haleon plc
 $40.25B -9.3% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
620
% held
66.9%
Reported
625 of 685
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
318
View
Short & Settlement
Short Interest Falling
Shares short
27.7M
Days to cover
5.3d
Change
-331.3K sh
View
Short Volume
Short vol %
26%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$49.8K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
55.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$22.7M
Buyers / Sellers
0 / 7
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 30, 2026
View
Financials
Financials
Revenue (FY)
$17.3B
Net income (FY)
$1.4B
EPS diluted
$1.21
View
Buybacks
Authorized
$2.1B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 3, 2026
This year
27

Teva Pharmaceutical Industries Ltd. reported third-quarter revenues of $4.4 billion, down 2% year-over-year, while AUSTEDO, AJOVY and UZEDY drove 33% growth; gross margin expanded to 55.5%, and the company raised 2026 revenue guidance to $16.7–$17.0 billion.

View
Proposed Sales
Value
$2.0M
Shares
44.7K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Teva Shares Innovative Pipeline U…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
TEVA +4.4% +7.2% +28.6% +5.7% +42.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +1.9% +8.4% +28.1% +5.9% +32.0%

Capital returns

Buyback program · as of Dec 31, 2017
Authorized
$2.10B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 818686 CUSIP M8769Q102 13F (30d) 513 filings 446 filers Visit website Investor relations